Filtered By:
Vaccination: Shingles (Herpes Zoster) Vaccine

This page shows you your search results in order of relevance. This is page number 7.

Order by Relevance | Date

Total 1783 results found since Jan 2013.

Incremental net monetary benefit of herpes zoster vaccination: a systematic review and meta-analysis of cost-effectiveness evidence
CONCLUSIONS: RZV may be cost-effective for vaccination in ages of 60-79 years for both SP and TPP perspectives, while ZVL might be cost-effective in some age groups, but results are not robust.PMID:34791974 | DOI:10.1080/13696998.2021.2008195
Source: Journal of Medical Economics - November 18, 2021 Category: Health Management Authors: Sariya Udayachalerm Maranda G Renouard Thunyarat Anothaisintawee Ammarin Thakkinstian Sajesh K Veettil Nathorn Chaiyakunapruk Source Type: research

Adult Vaccination as a Protective Factor for Dementia: A Meta-Analysis and Systematic Review of Population-Based Observational Studies
ConclusionRoutine adult vaccinations are associated with a significant reduction in dementia risk and may be an effective strategy for dementia prevention. Further research is needed to elucidate the causal effects of this association and the underlying mechanisms.
Source: Frontiers in Immunology - May 3, 2022 Category: Allergy & Immunology Source Type: research

Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news

Neuro-Ophthalmological Complications of the COVID-19 Vaccines: A Systematic Review
Conclusion: Since the implementation of the COVID-19 vaccination campaign in the past year, several post-COVID-vaccination neuro-ophthalmological complications have been described. However, considering the number of individuals that have been exposed to the vaccines, the risk seems very low, and the clinical outcome in most cases is favorable. Therefore, on a population level, the benefits of the vaccines far outweigh the risk of neuro-ophthalmological complications.
Source: Journal of Neuro-Ophthalmology - May 27, 2022 Category: Opthalmology Tags: Disease of the Year 2021 Encore: COVID-19 Source Type: research

Fight Aging! Newsletter, February 13th 2023
This study investigated whether taller Polish adults live longer than their shorter counterparts. Data on declared height were available from 848,860 individuals who died in the years 2004-2008 in Poland. To allow for the cohort effect, the Z-values were generated. Separately for both sexes, Pearson's r coefficients of correlation were calculated. Subsequently, one way ANOVA was performed. The correlation between adult height and longevity was negative and statistically significant in both men and women. After eliminating the effects of secular trends in height, the correlation was very weak (r = -0.0044 in men and ...
Source: Fight Aging! - February 12, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Impact of influenza, herpes zoster, and pneumococcal vaccinations on the incidence of cardiovascular events in subjects aged over 65  years: a systematic review
AbstractThis systematic review aims to summarize the impact of vaccination against influenza, shingles, and pneumococcus on the incidence on the risk of cardiovascular events in the elderly. This protocol was developed in accordance with PRISMA guidelines. We conducted a literature search and identified all relevant articles published regarding the matter up to September 2022. We retrieved 38 studies (influenza vaccine  = 33, pneumococcal vaccine = 5, and zoster vaccine = 2). A total of 28 and 2 studies have shown that influenza and pneumococcal vaccines significantly lower the risk of cardiovascular disease ...
Source: AGE - June 3, 2023 Category: Geriatrics Source Type: research

Surveillance of Vaccination Coverage Among Adult Populations -United States, 2018
MMWR Surveill Summ. 2021 May 14;70(3):1-26. doi: 10.15585/mmwr.ss7003a1.ABSTRACTPROBLEM/CONDITION: Adults are at risk for illness, hospitalization, disability and, in some cases, death from vaccine-preventable diseases, particularly influenza and pneumococcal disease. CDC recommends vaccinations for adults on the basis of age, health conditions, prior vaccinations, and other considerations. Updated vaccination recommendations from CDC are published annually in the U.S. Adult Immunization Schedule. Despite longstanding recommendations for use of many vaccines, vaccination coverage among U.S. adults remains low.REPORTING PER...
Source: MMWR Surveill Summ - May 13, 2021 Category: Epidemiology Authors: Peng-Jun Lu Mei-Chuan Hung Anup Srivastav Lisa A Grohskopf Miwako Kobayashi Aaron M Harris Kathleen L Dooling Lauri E Markowitz Alfonso Rodriguez-Lainz Walter W Williams Source Type: research